Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» stem cells
stem cells
FDA extends deadline to decide on Gamida Cell's stem cell transplant therapy by three months
FDA extends deadline to decide on Gamida Cell's stem cell transplant therapy by three months
Fierce Biotech
Gamida Cell
FDA
stem cells
stem cell transplant
Flag link:
Regenerative medicine clinical trials continue to rise
Regenerative medicine clinical trials continue to rise
Clinical Trials Arena
regenerative medicine
stem cells
clinical trials
Flag link:
Vertex Pharma (VRTX) to Acquire ViaCyte for $320 Million
Vertex Pharma (VRTX) to Acquire ViaCyte for $320 Million
Street Insider
Vertex Pharmaceuticals
M&A
ViaCyte
type 1 diabetes
stem cells
Flag link:
Research Shows Stem Cells Might Become a Game Changer for Multiple Sclerosis
Research Shows Stem Cells Might Become a Game Changer for Multiple Sclerosis
BioSpace
R&D
stem cells
multiple sclerosis
MS
Flag link:
Prettying itself up for partners, Athersys lays off 70% of staff and most of C-suite
Prettying itself up for partners, Athersys lays off 70% of staff and most of C-suite
Fierce Biotech
Athersys
layoffs
cell therapy
stem cells
Flag link:
FDA grants fast track designation for Priothera’s AML therapy
FDA grants fast track designation for Priothera’s AML therapy
Pharmaceutical Business Review
Priothera
mocravimod
stem cells
AML
Flag link:
Not an 'excellent outcome' for Athersys stock as stem cell therapy misses endpoint in Japanese trial
Not an 'excellent outcome' for Athersys stock as stem cell therapy misses endpoint in Japanese trial
Fierce Biotech
Arthersys
Healios
ischemic stroke
MultiStem
stem cells
Flag link:
Aiming to treat Parkinson’s by replacing neurons, Aspen Neuroscience nabs $147M
Aiming to treat Parkinson’s by replacing neurons, Aspen Neuroscience nabs $147M
MedCity News
Aspen Neuro
Parkinson's Disease
stem cells
Bayer
cell therapy
Flag link:
7 Medical Device Sectors Ripe for M&A
7 Medical Device Sectors Ripe for M&A
Medical Devices and Diagnostics Industry
devices
Medtech
M&A
TMVR
pulsed field ablation
digital therapeutics
artificial intelligence
thrombectomy
intraocular lenses
stem cells
regenerative medicine
Flag link:
EdiGene enters R&D collaboration to develop hematopoietic stem cell regenerative therapies
EdiGene enters R&D collaboration to develop hematopoietic stem cell regenerative therapies
Biopharma Reporter
EdiGene
R&D
Haihe Laboratory of Cell Ecosystem
hematopoietic
stem cells
Flag link:
Mesoblast pummelled as Novartis exits COVID deal
Mesoblast pummelled as Novartis exits COVID deal
Pharmaforum
Novartis
Mesoblast
stem cells
remestemcel-L
COVID-19
Flag link:
ViaCyte's Stem Cell-Derived Treatment for Type 1 Diabetes Shows Promising Results in Two Published Studies
ViaCyte's Stem Cell-Derived Treatment for Type 1 Diabetes Shows Promising Results in Two Published Studies
Drugs.com
ViaCyte
type 1 diabetes
clinical trials
stem cells
Flag link:
Vertex early phase 1/2 data shows promise for type 1 diabetes stem cell therapy
Vertex early phase 1/2 data shows promise for type 1 diabetes stem cell therapy
Seeking Alpha
Vertex Pharmaceuticals
VX-880
type 1 diabetes
stem cells
cell therapy
clinical trials
Flag link:
FDA rejects Omeros transplant drug over difficulties estimating its effect
FDA rejects Omeros transplant drug over difficulties estimating its effect
Fierce Biotech
FDA
organ transplant
stem cells
Omeros
Flag link:
FDA gives speedy review to Bayer’s Parkinson’s stem cell therapy
FDA gives speedy review to Bayer’s Parkinson’s stem cell therapy
Pharmaforum
Bayer
BlueRock Therapeutics
FDA
DA01
stem cells
Parkinson's Disease
Flag link:
Already sitting on a major stem cell bank, Generate looks to grow its regenerative medicines business
Already sitting on a major stem cell bank, Generate looks to grow its regenerative medicines business
Endpoints
Generate Life Sciences
stem cells
regenerative medicine
Flag link:
Fresh off $598M deal with Novo Nordisk, a Japanese stem cell company is on its way to the clinic with a different approach to treating heart failure
Fresh off $598M deal with Novo Nordisk, a Japanese stem cell company is on its way to the clinic with a different approach to treating heart failure
Endpoints
heart failure
Heartseed
Japan
Novo Nordisk
stem cells
Flag link:
FDA disappointed with slow uptake of approvals for stem cell therapies
FDA disappointed with slow uptake of approvals for stem cell therapies
RAPS.org
FDA
regulatory
stem cells
Flag link:
Magenta's R&D head hits the exit just weeks after reading out mid-stage data for lead therapy, eyeing clinic for another
Magenta's R&D head hits the exit just weeks after reading out mid-stage data for lead therapy, eyeing clinic for another
Endpoints
Magenta Therapeutics
stem cells
stem cell transplant
clinical trials
Flag link:
Tiny Beating Hearts Developed by Stem Cells Could Provide Insight Into Congenital Defects
Tiny Beating Hearts Developed by Stem Cells Could Provide Insight Into Congenital Defects
BioSpace
stem cells
organoids
cardioids
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »